title: Diabetes insipidus as first manifestation of primary central nervous system lymphoma.
authors.affiliation: Department of Neurology, Columbia Presbyterian Medical Center, New York Neurological Institute, NY.
authors.forename: C M
authors.initials: CM
authors.lastname: Balmaceda
authors.forename: M R
authors.initials: MR
authors.lastname: Fetell
authors.forename: J E
authors.initials: JE
authors.lastname: Selman
authors.forename: A J
authors.initials: AJ
authors.lastname: Seplowitz
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001921:Brain / Q000473:pathology*; D002528:Cerebellar Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000532:radiotherapy; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D003919:Diabetes Insipidus / Q000209:etiology* / Q000628:therapy / Q000652:urine; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D008223:Lymphoma / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000532:radiotherapy; D008279:Magnetic Resonance Imaging; D008297:Male; D013974:Thyroxine / Q000627:therapeutic use; D014667:Vasopressins / Q000652:urine; D017287:Ventriculoperitoneal Shunt; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014667:Vasopressins; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D003894:Deamino Arginine Vasopressin; D013974:Thyroxine; D006854:Hydrocortisone